Review Article

Association of CDKAL1 RS10946398 Gene Polymorphism with Susceptibility to Diabetes Mellitus Type 2: A Meta-Analysis

Ning Xu,1 Ting-Ting Zhang,1 Wen-Jia Han,2 Li-Ping Yin,3 Nan-Zheng Ma,4 Xiu-Yan Shi,5 and Jiang-Jie Sun6

1School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, China
2School of Dentistry, Anhui Medical University, Hefei, Anhui 230032, China
3Medical Examination Center, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
4Anhui Medical University, Affiliated Hospital, Nationalities, Hefei, Anhui 230032, China
5Nanjing Prevention and Treatment Center for Occupational Diseases, Nanjing 23100, China
6Health Management College, Anhui Medical University, Hefei, Anhui 230032, China

Correspondence should be addressed to Xiu-Yan Shi; wood20040@126.com and Jiang-Jie Sun; sunjiangjie@ahmu.edu.cn

Received 21 September 2021; Revised 12 November 2021; Accepted 13 November 2021; Published 24 December 2021

Academic Editor: Nikolaos Papanas

Copyright © 2021 Ning Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Diabetes is one of the common chronic diseases in which susceptibility is determined by a combination of genetic and environmental factors, and more than 90% of diabetic patients are diabetes mellitus type 2 (T2DM). The existing studies on the association between CDKAL1 rs10946398 gene polymorphism and susceptibility to type 2 diabetes are inconsistent across populations. Aim. We aim to explore the association between CDKAL1 rs10946398 gene polymorphism and susceptibility to type 2 diabetes in different populations. Methods. We examined all studies before June 12, 2021, that associated CDKAL1 rs10946398 with T2DM. Heterogeneity was assessed by meta-analysis of allelic inheritance models (A vs. C), dominant inheritance models (AA vs. AC+CC), and recessive inheritance model (AA+AC vs. CC); I² was used to assess the heterogeneity (if I² < 50%, the fixed-effects model was used; if I² ≥ 50%, the random-effects model was used for data consolidation); correlation was judged by a forest map; potential publication bias was tested by the Egger test (p > 0.05 indicates that there is no publication bias). Results. Fourteen data totaling 30288 subjects, including 19272 controls and 11016 patients with T2DM, met our inclusion criteria. In the Asian population, the differences were statistically significant (p < 0.01) for dominant genetic model (OR = 0.75, 95%CI = 0.64-0.88, p = 0.0003). But the allelic effect model (OR = 0.87, 95%CI = 0.75 -1.02, p = 0.08) and the recessive genetic model (OR = 0.85, 95%CI = 0.66-1.10, p = 0.28) were not statistically significant (p > 0.01). In the non-Asian population, the differences were statistically significant (p < 0.01) for the allelic effect model (OR = 0.83, 95%CI = 0.77-0.88, p < 0.00001), the dominant model (OR = 0.79, 95%CI = 0.72-0.87, p < 0.0001), and the recessive model (OR = 0.78, 95%CI = 0.70-0.87, p < 0.0001). Conclusion. In this study, CDKAL1 RS10946398 was positively associated with T2DM, but the association was different in Asian populations.

1. Introduction

According to the World Health Organization (WHO), approximately 3.4 million people died from developing diabetes in 2004, and it predicts that the number of diabetes deaths will double between 2005 and 2030. The International Diabetes Federation predicts that the global prevalence of diabetes will reach 642 million cases by 2040 (International Diabetes Federation, 2015), with type 2 diabetes accounting for more than 90% of diabetics [1].

Type 2 diabetes mellitus (T2DM), formerly known as non-insulin-dependent or adult-onset diabetes mellitus, is a type of diabetes mellitus. It is caused by poor insulin action which is the relative lack of insulin in patients, and its susceptibility is determined by both genetic and environmental factors [2]. In the context of increasing morbidity and
mortality of T2DM, it is of great significance to study the pathogenesis of T2DM.

Previous studies have shown that China [3–6] and other Populations of Asian countries’ CDKAL1 RS10946398 locus mutation was significantly associated with T2DM [1, 7–10]. The United States [11, 12], Russia [13, 14], Mexico [15], and other non-Asian populations of CDKAL1 RS10946398 were also significantly associated with T2DM. It is noteworthy that a variant of the CDKAL1 RS10946398 locus in the population of the Asian country of the United Arab Emirates may not be directly associated with the development of T2DM [1]. These show that CDKAL1 rs10946398 locus variants play different roles in different study populations. Therefore, it is of great significance to study the relationship between CDKAL1 rs10946398 locus variation and T2DM susceptibility in different populations.

1.1. Retrieval Strategy. An advanced search of the literature search library was conducted by using “T2DM CDKAL1” and “CDKAL1 rs10946398” as key to search terms in the China National Knowledge Infrastructure (CNKI), PubMed, and WanFang digital databases, with the last search conducted on June 12, 2021.

1.2. Inclusion and Exclusion Criteria. The following studies were included [16, 17]:

(1) Case-control studies focus on the association between the CDKAL1 rs10946398 polymorphism and T2DM in adults
(2) Patients were randomly selected with no special restrictions on gender, family history, etc.
(3) Studies provide accurate control and case group data sources
(4) The data provided in the study report were statistically significant. The study results had specific OR values, 95% CI
(5) Studies met the diagnostic criteria of T2DM published by the World Health Organization (WHO) in 2019, and the control group all met the law of H-W genetic balance

The following studies were excluded:

(1) There were only case groups or a lack of sufficient controls
(2) Statistical data are erroneous or there are significant differences in the statistics of the same study in different literatures
(3) The overall sample size is insufficient
(4) Literature reviews and case reports were excluded

1.3. Data Extraction. Two investigators independently read the literature and extracted information from the eligible literature based on exclusion and inclusion criteria. In case of ambiguity, a consensus was reached on whether to extract the paper data through discussion with the third investigator. For each paper, the following information was collected: (i) author’s name, (ii) year of publication, (iii) ethnicity and country of the study population, (vi) number of included cases and controls, and (vii) genotype data [3]. The literature screening process is shown in Figure 1.

1.4. Statistical Methods. Review Manager 5 software was used to complete the meta-analysis. Stata software was used to complete the Egger test.

2. Results

2.1. Baseline Characteristics of Included Studies. We obtained articles on the relationship between CDKAL1 rs10946398 diversity and T2DM susceptibility from PubMed and CNQ. After reading the title, year, author, and abstract of the papers, we conducted the first screening. The second screening was performed by reading the full text and analyzing whether the data was statistically significant. Finally, 14 literatures were included. A total of 14 datasets were obtained for meta-analysis by reading through the full text to filter the data required for recording. A total of 30,288 subjects were included in the meta-analysis, including a total of 11016 in the T2DM patient group and 19272 in the control group. Eight of the datasets were from the Asian study population: 3 from China, 1 from India, 1 from Korea, 1 from Japan, 1 from Iran, and 1 from the United Arab Emirates; 6 were from the non-Asian study population: 3 from the USA, 2 from Russia, and 1 from Mexico. Information on
| First author       | Region | Race | BMI              | Age (yr) | Controls | Cases | Controls | Cases | N  | AA | AC | CC | A  | C  | N  | AA | AC | CC | A  | C  |
|-------------------|--------|------|------------------|----------|----------|-------|----------|-------|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Horikoshi (2007)  | Asian  | Japanese | 23.8 ± 3.7 | 24.3 ± 3.9 | 69.5 ± 6.8 | 63.1 ± 9.5 | 861 | 280 | 423 | 158 | 983 | 739 | 852 | 239 | 434 | 179 | 912 | 792 |
| Joshua P (2008)   | Non-Asian | American | NA | NA | NA | NA | 1054 | 184 | 513 | 357 | 881 | 1227 | 993 | 147 | 470 | 376 | 764 | 1222 |
| Y. Liu (2008)     | Asian  | Chinese | 24.5 ± 3.2 | 25.3 ± 3.4 | 58.1 ± 9 | 63.8 ± 9 | 1822 | 588 | 862 | 372 | 2038 | 1606 | 1903 | 707 | 903 | 293 | 2317 | 1489 |
| Herder (2008)     | Non-Asian | American | 27.7 ± 4.3 | 30.9 ± 5.0 | 61.6 ± 9.7 | 59.9 ± 7.9 | 1438 | 705 | 604 | 129 | 2014 | 862 | 433 | 177 | 200 | 56 | 554 | 312 |
| Eun Seok (2009)   | Asian  | South Korea | NA | NA | 37.4 ± 9.3 | 42.6 ± 9.1 | 444 | 134 | 220 | 90 | 488 | 400 | 145 | 31 | 72 | 42 | 134 | 156 |
| Cheng Hu (2009)   | Asian  | Chinese | 23.57 ± 3.25 | 24.04 ± 3.51 | 57.39 ± 12.37 | 61.21 ± 12.62 | 1785 | 613 | 866 | 306 | 2092 | 1478 | 1850 | 578 | 912 | 360 | 2068 | 1632 |
| M. Cruz (2010)    | Non-Asian | Mexico | 27.50 ± 3.55 | 29.25 ± 4.76 | 43.60 ± 6.63 | 53.44 ± 7.42 | 548 | 270 | 229 | 49 | 769 | 327 | 519 | 242 | 225 | 52 | 709 | 329 |
| Ganesh (2010)     | Asian  | India | Women 24.90 (21.10–28.60) | Women 26.70 (24.20–29.20) | 50 (44–60) | 53 (45–62) | 1006 | 628 | 334 | 44 | 1590 | 422 | 1020 | 589 | 372 | 59 | 1550 | 490 |
| Dimitry A (2011)  | Non-Asian | Russian | 26.9 ± 4.8 | 28.3 ± 5.9 | 59.9 ± 7.9 | 26.9 ± 4.8 | 767 | 367 | 330 | 70 | 1064 | 470 | 769 | 333 | 337 | 99 | 1003 | 535 |
| Jessican (2012)   | Non-Asian | American | 29.5 ± 7.6 | 33.7 ± 7.6 | 48.6 ± 13.0 | 46.0 ± 12.3 | 567 | 105 | 278 | 184 | 488 | 646 | 1150 | 175 | 547 | 428 | 897 | 1403 |
| Aleksey G Nikitin (2017) | Non-Asian | Russian | 28.7 ± 4.8 | 30.5 ± 5.0 | 54.4 ± 11.0 | 60.0 ± 10.2 | 443 | 297 | 124 | 22 | 718 | 168 | 862 | 500 | 293 | 69 | 1293 | 431 |
| Oswald Ndi Nfor (2018) | Asian | Taiwanese women | NA | NA | 47.60 ± 10.80 | 55.56 ± 9.19 | 8934 | 3707 | 4061 | 1166 | 11475 | 6393 | 974 | 353 | 441 | 180 | 1147 | 801 |
| Mariam Al Ali (2019) | Asian | Emirati | NA | NA | NA | NA | 264 | 137 | 99 | 28 | 373 | 155 | 153 | 86 | 57 | 10 | 229 | 77 |
| Kazem Vatankhah Yazdi (2020) | Asian | Iranian | 23.07 ± 1.03 | 24.00 ± 1.23 | 65.5 ± 7.3 | 65 ± 7.5 | 106 | 46 | 50 | 10 | 142 | 70 | 162 | 31 | 104 | 27 | 166 | 158 |
the first author, study year, sample size, ethnicity, BMI, mean age of control and case groups, and risk allele frequency for each study is shown in Table 1.

### 3. Results of Meta-Analysis

In the evaluation of the relationship between the CDKAL1 rs10946398 gene and T2DM susceptibility, a total of 14 studies were included in the meta-analysis after literature data search, screening, and verification. In order to analyze the association between CDKAL1 rs10946398 polymorphism and susceptibility to T2DM, we analyzed the relationships between A and C alleles, AA+AC and CC genotypes, AA and AC+CC genotypes in T2DM patients and controls. Since 8 studies were from Asia and 6 were from non-Asia, we stratified the Asian and non-Asian populations.

We examined heterogeneity separately for the study populations, using $I^2$, to assess the magnitude of heterogeneity (if $I^2 < 50\%$, a fixed-effects model was used; if $I^2 \geq 50\%$, a random-effects model was used to combine the data). Because our data were randomly selected and we wanted to reflect the overall situation with a small sample size, only

![Table 2: Heterogeneity test.](image)

**Figure 2:** Forest plot of meta-analysis of the A vs. C allele model associated with T2DM at CDKAL1 rs10946398 locus.
the allelic genetic model and the recessive genetic model in non-Asian populations show that $I^2 < 50\%$, so we used the random-effects model (see Table 2).

In the total population, the differences were statistically significant ($p < 0.01$) for the allelic genetic models ($OR = 0.85, 95\%CI = 0.77-0.94$, $p = 0.001$), the dominant genetic models ($OR = 0.79, 95\%CI = 0.72-0.85$, $p < 0.00001$), and the recessive genetic models ($OR = 0.81, 95\%CI = 0.69-0.94$, $p = 0.007$). The results are shown in Figures 2–4.

In the Asian population, the differences were statistically significant ($p < 0.01$) for dominant genetic model ($OR = 0.75, 95\%CI = 0.64-0.88$, $p = 0.0003$). But the allelic effect model ($OR = 0.87, 95\%CI = 0.75-1.02$, $p = 0.08$) and the recessive genetic model ($OR = 0.85, 95\%CI = 0.66-1.10$, $p = 0.23$) were not statistically significant ($p > 0.01$). The results are shown in Figures 2–4.

In non-Asian populations, the differences were statistically significant ($p < 0.01$) for the allelic genetic model ($OR = 0.83, 95\%CI = 0.77-0.88$, $p < 0.00001$), the dominant genetic model ($OR = 0.79, 95\%CI = 0.72-0.87$, $p < 0.00001$), and the recessive genetic model ($OR = 0.78, 95\%CI = 0.70-0.87$, $p < 0.00001$). The results are shown in Figures 2–4.

3.1. Publication Bias. We used Stata software for the Egger test, and the $p$ values of allelic inheritance models (A vs. C), recessive inheritance model (AA+AC vs. CC), and dominant inheritance models (AA vs. AC+CC) were 0.114, 0.307, and 0.304, respectively, which were greater than 0.05, indicating that there was no publication bias. What is more, according to the symmetry of the funnel plot, the existence of publication bias can also be judged. The results are shown in Figures 5–7; it can be found that all points in the funnel plot are distributed symmetrically along both sides of the midline, so there is no bias.

4. Discussion

According to a large number of genome-wide association analyses (GWAS), CDK5 regulation-related protein 1-LIAK 1 (CDKAL1) gene under the action of high glucose toxicity will increase the body’s demand for insulin, and pancreatic $\beta$ cells continue to be activated, which may inhibit the activity of CDK5 in pancreatic $\beta$ cells. Insulin secretion is reduced by lowering the expression of insulin genes [18, 19]. Because mutations in CDKAL1 may lead to impaired insulin secretion, thus, it increases the risk of T2DM, and CDK5 regulates the related protein 1-LIAK 1 (CDKAL1) gene which is one of the most repeatable risk genes in T2DM [20]. In particular, SNPs rs10946398 and rs7754840 of CDKAL1 have the strongest correlation with T2DM [20].

To study the relationship between the variation of CDKAL1 RS10946398 locus and the susceptibility to T2DM in different populations, 14 sets of data were finally used for meta-analysis through data investigation and screening, and 13 sets of data showed that the CDKAL1
RS10946398 locus was significantly correlated with the incidence of T2DM; for example, a study by Nfor et al. showed a significant association between CDKAL1 RS10946398 and T2DM in Taiwanese. CC carriers were more associated with T2DM than AC carriers, and C allele carriers were more associated with type 2 diabetes than A allele carriers [6]. A study by Herder et al. found that CDKAL1rs10946398 was significantly associated with impaired glucose metabolism or β cell function. CDKAL1rs10946398 also plays an important role in the pathogenesis of T2DM in the detected Russian population [12]. Only one set of data showed that CDKAL1 RS10946398 locus was not significantly associated with the pathogenesis of T2DM. The study by Al Ali et al. showed that the CDKAL1 RS9939609 variant in the United Arab Emirates population may not be directly related to the development of T2DM [1]. Therefore, the role of CDKAL1 rs10946398 locus variation in different study populations is different.

In this study, a meta-analysis of the included 14 groups of data concerning the CDKAL1 rs10946398 locus and T2DM was performed by analyzing allelic models (A vs. C), recessive genetic models (AA+AC vs. CC), and dominant genetic models (AA vs. AC+CC) in T2DM patients and controls.

| Study or subgroup | Cases Events | Cases Total | Control Events | Control Total | Weight | M-H, random, 95% CI | Odds ratio M-H, random, 95% CI |
|-------------------|--------------|-------------|----------------|---------------|--------|---------------------|--------------------------------|
| 1.1.1 Asian       | 2068 3700    | 2092 3570   | 134 290        | 488 888       | 7.7    | 0.84 [0.72, 0.97]    |                                 |
| Eun Seok 2009     | 1550 2040    | 1590 2012   | 1506 2040      | 1590 2012     | 7.7    | 0.84 [0.72, 0.97]    |                                 |
| Kazem Vatankhah Yazdi 2020 | 166 324 | 142 212 | 912 1704 | 983 1722 | 4.1    | 0.87 [0.76, 0.99]    |                                 |
| Miriam Al Ali 2019 | 229 306 | 373 528 | 1147 1948 | 11475 17868 | 4.6    | 0.80 [0.73, 0.88]    |                                 |
| Y. Liu 2008        | 2317 3806    | 2038 3644   | 14118 30444    | 55.3%        | 0.87 [0.75, 1.02]    |                                 |
| Total events       | 8523         | 19181       |                |               |        |                     |                                 |

Test for overall effect: Z = 1.73 (P = 0.08)

1.1.2 Non-asian

| Study or subgroup | Cases Events | Cases Total | Control Events | Control Total | Weight | M-H, random, 95% CI | Odds ratio M-H, random, 95% CI |
|-------------------|--------------|-------------|----------------|---------------|--------|---------------------|--------------------------------|
| Aleksey G Nikitin 2017 | 1293 1724 | 718 886 | 1003 1538 | 1064 1534 | 6.7    | 0.70 [0.57, 0.86]    |                                 |
| Dimitri A 2011     | 554 866      | 2014 2876   | 897 2300       | 488 1134      | 7.4    | 0.76 [0.65, 0.89]    |                                 |
| Herder 2008        | 764 1986     | 881 2108    | 709 1038       | 769 1096      | 7.0    | 0.92 [0.76, 1.10]    |                                 |
| Subtotal (95% CI)  | 9452 9634    | 44.5%       |                |               |        |                     |                                 |
| Total events       | 5220         | 5934        |                |               |        |                     |                                 |

Test for overall effect: Z = 5.55 (P < 0.00001)

Figure 4: Meta-analysis of a T2DM-associated AA+AC vs. CC genotype model at CDKAL1 RS10946398 locus forest map.

Figure 5: A vs. C allelic funnel plot.

Figure 6: AA vs. AC+CC genotype funnel plot.
controls and 11016 T2DM patients, we found that CDKAL1 rs10946398 gene polymorphism locus is associated with type 2 diabetes mellitus in different ethnic groups, and the degree of correlation is different in different genetic models. In the Asian population, the differences were statistically significant ($p < 0.01$) for the dominant genetic model (OR = 0.75, 95%CI = 0.64-0.88, $p = 0.0003$). But the allelic effect model (OR = 0.87, 95%CI = 0.75-1.02, $p = 0.08$) and the recessive genetic model (OR = 0.85, 95%CI = 0.66-1.10, $p = 0.23$) were not statistically significant ($p > 0.01$). The risk ratio of the A allele was higher than that of the C allele [21].

We used 14 sets of data for meta-analysis of the locus genetic model (A vs. C) recessive models (AA+AC vs. CC) and dominant models (AA vs. AC+CC). Except for the Asian allelic effect model and recessive gene model ($p > 0.01$), other models were statistically significant ($p < 0.01$). CDKAL1rs10946398 could significantly increase the risk of T2DM in the allele model of Asian and in all models of non-Asian. But this result cannot be attributed to differences in ethnicity; it could also be due to the small sample size. In conclusion, the CDKAL1 rs10946398 gene variant may increase the susceptibility to T2DM.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

NX and TZ designed this study. NX and TZ searched databases and collected full-text papers. NX, WH, and JD extracted and analyzed data. JS provided guidance for statistical analysis. NX wrote the manuscript. NX, LY, NM, XS, and TZ reviewed the manuscript. JS and XS have provided financial support for this work. NX and TZ contributed equally to this work.

**Acknowledgments**

This work was supported in part by the Nanjing Project of Medical Science and Technology Development (No. YK17207), Scientific Research Project of Nanjing Science and Technology Development Plan (No. 201803041), Natural Science Foundation of Anhui Province of China (No. 1908085MG233), Quality Engineering for research projects of the Anhui Department of Education (Nos. 2020SJXSFK1341 and 2020wyxm108), and the Natural Science Foundation for the Higher Education Institutions of Anhui Province of China (No. KJ2019A0945).

**References**

[1] M. al Ali, S. el hajj Chehadeh, W. Osman et al., “Investigating the association of rs7903146 of TCF7L2 gene, rs5219 of KCNJ11 gene, rs10946398 of CDKAL1 gene, and rs9939609 of FTO gene with type 2 diabetes mellitus in Emirati population,” Meta Gene, vol. 21, no. 9, article 100600, 2019.

[2] M. Malecki, “Genetics of type 2 diabetes mellitus,” *Diabetes Research and Clinical Practice*, vol. 68, no. 3, pp. S10–S21, 2005.

[3] Y. Liu, L. Yu, D. Zhang et al., “positive association between variations in CDKAL1 and type 2 diabetes in Han Chinese individuals,” *Diabetologia*, vol. 51, no. 11, pp. 2134–2137, 2008.

[4] C. Hu, R. Zhang, C. Wang et al., “PPARG, KCNJ11, CDKAL1, CDKN2A–CDKN2B, IDE–KIF11–HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a Chinese population,” *PloS One*, vol. 4, no. 10, pp. 1–6, 2009.

[5] Y. Lin, P. Li, L. Cai et al., “Association study of genetic variants in eight genes/loci with type 2 diabetes in a Han Chinese population,” *BMC Medical Genetics*, vol. 11, no. 1, pp. 1–8, 2010.

[6] O. N. Nfor, M. F. Wu, C. T. Lee et al., “Body mass index modulates the association between CDKAL1 rs10946398 variant and type 2 diabetes among Taiwanese women,” *Scientific Reports*, vol. 8, no. 1, pp. 1–8, 2018.

[7] K. Vatankhah Yazdi, S. M. Kalantar, M. Houshmand et al., “SLC30A8, CDKAL1, TCF7L2, KCNQ1 and IGF2BP2 are associated with type 2 diabetes mellitus in Iranian Patients,” *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 13, no. 3, pp. 897–906, 2020.

[8] E. S. Kang, M. S. Kim, C. H. Kim et al., “Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea,” *Transplantation*, vol. 88, no. 5, pp. 693–698, 2009.

[9] M. Horikoshi, K. Hara, C. Ito et al., “Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population,” *Diabetologia*, vol. 50, no. 12, pp. 2461–2466, 2007.

[10] G. Chauhan, C. J. Spurgeon, R. Tabassum et al., “Impact of common variants ofPPARG,KCNJ11,TCF7L2,SLC30A8,H-HEX,CDKN2A,IGF2BP2, andCDKAL1on the risk of type 2 diabetes in 5,164 Indians,” *Diabetes*, vol. 59, no. 8, pp. 2068–2074, 2010.
[11] J. P. Lewis, N. D. Palmer, P. J. Hicks et al., "Association analysis in African Americans of European-derived type 2 diabetes single nucleotide polymorphisms from whole-genome association studies," *Diabetes*, vol. 57, no. 8, pp. 2220–2225, 2008.

[12] C. Herder, W. Rathmann, K. Strassburger et al., "Variants of thePPARG,IGF2BP2,CDKAL1,HHEX, andTCF7L2Genes confer risk of type 2 diabetes independently of BMI in the German KORA studies," *Hormone and Metabolic Research*, vol. 40, no. 10, pp. 722–726, 2008.

[13] D. A. Chistiakov, V. A. Potapov, S. A. Smetanina, L. N. Bel’chikova, L. A. Suplotova, and V. V. Nosikov, "The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel," *Acta Diabetologica*, vol. 48, no. 3, pp. 227–235, 2011.

[14] A. G. Nikitin, V. Y. Potapov, O. I. Brovkina et al., "Association of polymorphic markers of genesFTO, KCNJ11, CDKAL1, SLC30A8,andCDKN2Bwith type 2 diabetes mellitus in the Russian population," *Peer J*, vol. 5, no. 9, article e3414, 2017.

[15] M. Cruz, J. Valladares-Salgado, J. Garcia-Mena et al., "Candidate gene association study conditioning on individual ancestry in patients with type 2 diabetes and metabolic syndrome from Mexico City," *Diabetes/Metabolism Research and Reviews*, vol. 26, no. 4, pp. 261–270, 2010.

[16] X. Liu, J. Liang, H. Geng, W. Xu, F. Teng, and M. Yang, "Association of the CDKAL1 polymorphism rs10946398 with type 2 diabetes mellitus in adults," *Medicine*, vol. 99, no. 30, pp. e21383–e21388, 2020.

[17] M. A. S. Dehwah, M. Wang, and Q.-Y. Huang, "CDKAL1 and type 2 diabetes: a global meta-analysis," *Genetics and Molecular Research*, vol. 9, no. 2, pp. 1109–1120, 2010.

[18] V. Lyssenko, A. Jonsson, P. Almgren et al., "Clinical risk factors, DNA variants, and the development of type 2 diabetes," *The New England Journal of Medicine*, vol. 359, no. 21, pp. 2220–2232, 2008.

[19] M. J. Groenewoud, J. M. Dekker, A. Fritsche et al., "Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps," *Diabetologia*, vol. 51, no. 9, pp. 1659–1663, 2008.

[20] F. Y. Wei and K. Tomizawa, "Functional loss of Cdkal1, a novel tRNA modification enzyme, causes the development of type 2 diabetes [review]," *Endocrine Journal*, vol. 58, no. 10, pp. 819–825, 2011.

[21] T. Muhadasi, M. Patamu, and M. Tuolanguli, "Association of CDKAL1 rs10946398 C/A polymorphism with type 2 diabetes," *Journal of Shandong University (Health Sciences)*, vol. 54, no. 2, pp. 75–85, 2016.